Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSC) Non-Current Debt (2020 - 2022)

Historic Non-Current Debt for Ensysce Biosciences (ENSC) over the last 3 years, with Q4 2022 value amounting to $140148.0.

  • Ensysce Biosciences' Non-Current Debt fell 9684.42% to $140148.0 in Q4 2022 from the same period last year, while for Dec 2022 it was $140148.0, marking a year-over-year decrease of 9684.42%. This contributed to the annual value of $140148.0 for FY2022, which is 9684.42% down from last year.
  • As of Q4 2022, Ensysce Biosciences' Non-Current Debt stood at $140148.0, which was down 9684.42% from $1.4 million recorded in Q3 2022.
  • In the past 5 years, Ensysce Biosciences' Non-Current Debt ranged from a high of $4.4 million in Q4 2021 and a low of $140148.0 during Q4 2022
  • Moreover, its 3-year median value for Non-Current Debt was $566268.0 (2020), whereas its average is $1.3 million.
  • As far as peak fluctuations go, Ensysce Biosciences' Non-Current Debt surged by 27340.11% in 2021, and later tumbled by 9684.42% in 2022.
  • Quarter analysis of 3 years shows Ensysce Biosciences' Non-Current Debt stood at $566268.0 in 2020, then soared by 684.25% to $4.4 million in 2021, then plummeted by 96.84% to $140148.0 in 2022.
  • Its Non-Current Debt was $140148.0 in Q4 2022, compared to $1.4 million in Q3 2022 and $360797.0 in Q2 2022.